Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLRXNASDAQ:IPSCNASDAQ:PEPGNASDAQ:RVPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$3.79+3.0%$3.11$2.30▼$35.60$12.62M1.1567,819 shs19,295 shsIPSCCentury Therapeutics$0.56-0.3%$0.51$0.34▼$3.46$48.25M1.8475,228 shs317,604 shsPEPGPepGen$1.58+7.5%$1.41$0.88▼$19.30$51.70M1.39825,213 shs265,755 shsRVPHReviva Pharmaceuticals$1.12+1.8%$0.83$0.49▼$4.28$52.35M0.081.13 million shs429,014 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx+2.99%+4.41%+18.25%+14.16%-86.82%IPSCCentury Therapeutics-0.28%-3.38%+12.54%-16.73%-83.03%PEPGPepGen+7.48%+9.72%-1.25%-34.98%-89.10%RVPHReviva Pharmaceuticals+1.82%+13.13%+28.68%-21.68%-18.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLRXBioLineRx2.5316 of 5 stars3.34.00.00.02.60.01.3IPSCCentury Therapeutics2.3635 of 5 stars3.53.00.00.01.91.70.6PEPGPepGen2.3555 of 5 stars3.22.00.00.01.82.51.3RVPHReviva Pharmaceuticals3.1515 of 5 stars3.63.00.00.02.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLRXBioLineRx 2.50Moderate Buy$26.00586.02% UpsideIPSCCentury Therapeutics 3.00Buy$4.20650.00% UpsidePEPGPepGen 2.33Hold$9.67511.81% UpsideRVPHReviva Pharmaceuticals 3.29Buy$9.00703.57% UpsideCurrent Analyst Ratings BreakdownLatest BLRX, IPSC, RVPH, and PEPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/20/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $3.005/16/2025IPSCCentury TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $6.005/9/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $14.004/24/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/3/2025IPSCCentury TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $2.004/2/2025BLRXBioLineRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/1/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $8.003/31/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $26.003/28/2025IPSCCentury TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/24/2025IPSCCentury TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $7.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLRXBioLineRx$28.94M0.44N/AN/A$7.30 per share0.52IPSCCentury Therapeutics$114.90M0.42N/AN/A$3.06 per share0.18PEPGPepGenN/AN/AN/AN/A$4.55 per shareN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/A$0.20 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLRXBioLineRx-$60.61M-$8.80N/AN/AN/A-90.57%-163.37%-34.21%8/15/2025 (Estimated)IPSCCentury Therapeutics-$136.67M-$0.29N/AN/AN/A-4,837.73%-61.66%-31.78%8/14/2025 (Estimated)PEPGPepGen-$78.63M-$3.13N/AN/AN/AN/A-60.17%-48.88%8/14/2025 (Estimated)RVPHReviva Pharmaceuticals-$39.26M-$0.79N/AN/AN/AN/AN/A-252.53%8/13/2025 (Estimated)Latest BLRX, IPSC, RVPH, and PEPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2025Q1 2025BLRXBioLineRx-$0.84$1.39+$2.23$1.39$7.72 million$11.75 million5/15/2025Q1 2025IPSCCentury Therapeutics-$0.31$0.89+$1.20$0.89$45.52 million$109.16 million5/15/2025Q1 2025RVPHReviva Pharmaceuticals-$0.21-$0.13+$0.08-$0.13N/AN/A5/8/2025Q1 2025PEPGPepGen-$0.72-$0.92-$0.20-$0.92N/AN/A3/31/2025Q4 2024RVPHReviva Pharmaceuticals-$0.22-$0.15+$0.07-$0.15N/AN/A3/19/2025Q4 2024IPSCCentury Therapeutics-$0.45-$0.43+$0.02-$0.43$0.67 million$4.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLRXBioLineRxN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLRXBioLineRx2.111.521.37IPSCCentury TherapeuticsN/A10.3910.39PEPGPepGenN/A8.478.47RVPHReviva PharmaceuticalsN/A0.390.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLRXBioLineRx1.56%IPSCCentury Therapeutics50.20%PEPGPepGen58.01%RVPHReviva Pharmaceuticals63.18%Insider OwnershipCompanyInsider OwnershipBLRXBioLineRx1.10%IPSCCentury Therapeutics6.80%PEPGPepGen5.20%RVPHReviva Pharmaceuticals27.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLRXBioLineRx403.33 million3.29 millionOptionableIPSCCentury Therapeutics17086.16 million79.25 millionOptionablePEPGPepGen3032.72 million31.10 millionNot OptionableRVPHReviva Pharmaceuticals546.74 million24.35 millionOptionableBLRX, IPSC, RVPH, and PEPG HeadlinesRecent News About These CompaniesWhat is Zacks Small Cap's Forecast for RVPH Q2 Earnings?May 27 at 1:25 AM | americanbankingnews.comResearch Analysts Set Expectations for RVPH Q2 EarningsMay 24, 2025 | americanbankingnews.comD. Boral Capital Has Lowered Expectations for Reviva Pharmaceuticals (NASDAQ:RVPH) Stock PriceMay 22, 2025 | americanbankingnews.comReviva to Participate in Upcoming Investor Conferences in May 2025May 20, 2025 | santelog.comAnalysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Price Target at $10.00May 19, 2025 | americanbankingnews.comReviva Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 15, 2025 | globenewswire.comReviva to Participate in the A.G.P. Healthcare Company ShowcaseMay 13, 2025 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Icon (ICLR), Reviva Pharmaceuticals Holdings (RVPH) and SurModics (SRDX)May 4, 2025 | theglobeandmail.comReviva to Participate in the Citizens Life Sciences ConferenceApril 29, 2025 | finance.yahoo.comRVPH: M&A Deals Highlight Brilaroxazine ValueApril 7, 2025 | finance.yahoo.comRoth MKM Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)April 5, 2025 | markets.businessinsider.comReviva Reports Full Year 2024 Financial Results and Recent Business HighlightsMarch 31, 2025 | markets.businessinsider.comReviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS CongressMarch 30, 2025 | globenewswire.comWhy Reviva Pharmaceuticals Holdings, Inc.’s (RVPH) Stock Is Down 10.61%March 7, 2025 | aaii.comUnusually active option classes on open February 12thFebruary 12, 2025 | markets.businessinsider.comReviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comReviva to Participate in the 2025 BIO CEO & Investor ConferenceJanuary 30, 2025 | globenewswire.comReviva Pharmaceuticals price target lowered to $11 from $14 at H.C. WainwrightJanuary 22, 2025 | markets.businessinsider.comReviva Pharmaceuticals Holdings Inc (RVPH) Stock Sees Market Value Hit $93.16 million: What Are the Implications?January 22, 2025 | bovnews.comROTH MKM Issues Buy Rating for Reviva Pharmaceuticals Holdings Inc (RVPH) StockJanuary 18, 2025 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBLRX, IPSC, RVPH, and PEPG Company DescriptionsBioLineRx NASDAQ:BLRX$3.79 +0.11 (+2.99%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$3.77 -0.02 (-0.55%) As of 05/28/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Century Therapeutics NASDAQ:IPSC$0.56 0.00 (-0.28%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$0.60 +0.04 (+7.14%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.PepGen NASDAQ:PEPG$1.58 +0.11 (+7.48%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.38 -0.20 (-12.59%) As of 06:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.Reviva Pharmaceuticals NASDAQ:RVPH$1.12 +0.02 (+1.82%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.01 -0.11 (-10.18%) As of 06:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
